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Abstract Evidence-basedmedicinehasbeendescribedas the‘‘conscientious, explicit andjudicioususe ofcurrentbest
evidence in making decisions about the healthcare of individual patients.’’Many sources of information may be used by
doctorswhenmaking decisions about initiating asthma therapy.These include: personal experience, postgraduate edu-
cation, continuousprofessionaldevelopment andpublicationsinpeer-reviewedjournals.However, despitethese sources
of information, available data suggestthat it is often di⁄cultto practice evidence-basedmedicine, particularly in general
practice.Inthe future, physicianswillbeprovidedwithbetterevidence oftherelative e⁄cacyoftreatmentto aid changes
in clinical practice.This will be provided, in part, by large well-conducted clinical trials, systematic reviews and meta-
analyses. Linked with these, will be other methods of presenting data, for example, the number of patients needed to
treat (NNT) to prevent one clinically signi¢cant event (for example, an asthma exacerbation).Despite these advances,
incorporation of evidence-based practice into routine asthma care will be a slow and complex process.However, this
processcanbe facilitatedbyphysicianeducationandparticipationininterventionprogrammes.In addition, itisimportant
thatclinicians are trained inhow to convey the bestpossible evidence totheir asthma patients.r2002 Elsevier Science Ltd.All
rights reserved.
doi:10.1053/rmed.2002.1349, available online at http://www.idealibrary.comon
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Evidence-based medicine has been de¢ned by Sackett
and colleagues as the ‘‘conscientious, explicit and judi-
cious use of current best evidence in making decisions
about the care of individual patients’’ (1). To achieve this
standard of practice, clinicians should act upon evidence
as it becomes available, weigh the evidence in a consis-
tent and validmanner and then change their practice ap-
propriately.This simple description hides a very complex
system with many steps between the collection of evi-
dence and the prescription of a speci¢c therapeutic in-
tervention by an individual clinician for a speci¢c
patient. A few of these steps will be highlighted in this
paper that aims to address issues around asthma man-
agement.Much of the literature in the ¢eld has been de-
rived from diseases other than asthma, although the
same general principles apply to physician practiceReceived 30 July 2001, accepted in revised form19 February 2002.
Correspondence should be addressed to: Paul W. Jones, St.George’s
Hospital Medical School,CranmerTerrace, London SW17 0RE,U.K.




Behind the de¢nition of evidence-basedmedicine quoted
above, the reader senses the authors’ belief that good
and e¡ectivepractice is theprime objective ofmost clin-
icians.This objective may not be held universally, as evi-
denced by a recent study in British general practice (2).
This qualitative study identi¢ed a number of reasonswhy
it may be di⁄cult to apply evidenced-based medicine in
general practice. The general practitioner’s (GP) de¢ni-
tions of e¡ective care fell into three categories: clinical,
patientrelated andresourcerelated. In contrast, theper-
spective of Sackett et al. appears more clinician-centred
(1).The BritishGPs’main reasons for notpracticing e¡ec-
tively were patient factors such as their preferences and
circumstances.Other factors included lack of time, lack
of knowledge and skills, lack of resources and ‘‘human
failings’’. The authors of this gloomy report concluded
TABLE 1. Sources given as reasons for changing practice
(% of total by clinical group).The di¡erence in distribution of





Scienti¢c/medical journal 16 36
Medicalnewspaper 21 0
Scienti¢cmeeting/conference 1 20
Postgraduate course 30 8
Protocols andguidelines 8 2
Audit 5 6
Others andunspeci¢ed 19 28
568 RESPIRATORYMEDICINEthat the central assumptions of the evidenced-based
model of caremight not be sharedbymany GPs.
REASONSFORHAVINGCHANGED
PRACTICE
In the study just discussed, the main sources of informa-
tion in cases of clinicaluncertainty were general practice
partners and hospital doctors (2). Another qualitative
study in general practice (3) identi¢ed three models of
change in clinical practice:
K An accumulating evidencemodel inwhich volume and
authority of evidence are important. Sources of
evidence include the British Medical Journal, The
Drugs and Therapeutics Bulletin (a British
government funded evidenced-based treatment
newsletter sent regularly to all doctors), trusted
consultants and new GP partners (because they had
been exposed most recently to new ideas and
personal experience).
K A continuity model, which comprised a willingness to
change coupled with cost pressures and an
understanding of the therapeutic action of the drug.
K A challenge model, this was typi¢ed as a change
following a dramatic event.
Another studyused a critical incident technique to es-
tablish reasons why GPs and hospital consultants chan-
ged their clinical practice (4). This study illustrated the
multiplicity and complexity of events surrounding a
change.On average, there were three reasons for each
change.The three most frequently mentioned were or-
ganizational factors, education and contact with profes-
sionals. These accounted for half of the reasons for
change.Education, the broad area intowhich the Sackett
de¢nition of evidenced-based medicine falls, accounted
for one-sixth of the reasons to change and contributed
to less than 40% of the changes. Re-examination of the
data presentedbyAlleryetal. (4)) shows that there were
statistically signi¢cant di¡erences in sources of evidence
given by GPs and hospital doctors as their reason for
changing practice (Table1).
In the studies just quoted, doctorswere questioned as
to their reasons for changing their practice. It is reason-
able therefore to look for evidence that publishing clini-
cal trial data can alter clinical practice. Perhaps one of
the best pieces of evidence comes from an opportunistic
evaluation (5) of the impact of three studies in coronary
artery disease, all published in1988. (6^8).One trial re-
ported that aspirin reduced the risk of a ¢rstmyocardial
infarction (MI), the second supported the use of aspirin
after anMI and the thirdreported an adverse e¡ectwith
diltiazem (a calciumchannelblocker)whenusedpost-MI .
Between 1987 and 1990, the use of aspirin both before
and after an MI rose signi¢cantly, and the use of calciumantagonists post-MI decreased signi¢cantly (5). Thus,
publication in a major journal (a favoured source of evi-
dence for hospital consultants) had quite a rapid and sig-
ni¢cant e¡ect on practice. For example, the use of
aspirin post-MI increased from 39 to 72% of patients and
theuse of calcium antagonists decreased from 57 to 33%.
PRESENTINGTHEEVIDENCEFOR
TREATMENTEFFICACY
Evidencehas to bepresented in someway, andbecause it
is usually numerical, graphical presentation is often used.
A recent study found that the choice of display format
in£uenced decisions to stop clinical trials (9). A simple
icon display was universally notpreferredby the respon-
dents as the graphic of choice, but it resulted in correct
responses being made from the data in 82% of cases. In
contrast, a table formatwas preferredby 62% of respon-
dents, but its use was associated fewer correct re-
sponses (68%). It is noteworthy that in this study
concerning decisions to stop clinical trials, more correct
decisions were made when the data were negatively
framed in tables than positively framed.
One of the favoured methods of presenting data for
evidenced-based medicine is the meta-analysis chart, as
exempli¢ed in Fig. 1 (10). This particular chart is taken
from the Cochrane Library and shows the results of a
meta-analysis of the overall e¡ects of comprehensive
asthma self-managementprogrammes (includingwritten
self-management plans), on hospital admissions. It can be
seen that, whilst two of the studies did not achieve sta-
tistical signi¢cance (i.e. the lower 95% con¢dence inter-
vals included the zero di¡erence line), the overall e¡ect
was signi¢cant. This is quite powerful evidence, that
should in£uence asthma management, but how does a
busy clinician interpret such data ? How big is the e¡ect
andwhat is a Peto odds ratio?
In recent years, there has been considerable
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FIG 1. Meta-analysis of four randomized controlled trials of
asthma management care programmes that included written
self-management plans.The trial names are on the left.The out-
comeis the oddsratio for theriskof hospital admission.The hor-
izontal lines indicate the 95% con¢dence limits around themean
oddsratio.The arrow for theuppermost studyindicates thatthe
meanvalue lies further to the leftthan can be shown in this plot.
Thisgraph is derived from Ref. (10).
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care. For example, data from the Helsinki Heart Study
were presented as absolute event data or as a relative
risk reduction to clinicians who were asked to judge the
e¡ectiveness of the treatment (11). Ratings of e¡ective-
ness were signi¢cantly lower when the data were pre-
sented as an absolute reduction. A similar observation
was made when health authority members were asked
to indicate their support for cardiac rehabilitation (12).
Therewas stronger support when the bene¢ts were ex-
pressed as a relative risk reduction than as an absolute
risk reduction. In this study, the results were also ex-
pressed as the number needed to treat (NNT) to pre-
vent an event. When presented in this way, more
support was given than when the data were presented
as an absolute risk reduction, but less than when they
were presented as a relative risk reduction.
EXPRESSINGEFFICACYOFASTHMA
TREATMENTASNNTS
The concept of the NNT has recently been applied to
asthma to describe the number of patients who would
have to be treated with salmeterol to experience an im-
provement in health-related quality of life that was at or
above the minimum clinically important di¡erence (13).
However, theremay be a danger in this approach, unless
clinicians receive adequate education regarding the
NNTs achievable with di¡erent treatments for chronic
disease.Guyatt et al. (13) calculated the NNT for salme-terol to be 4.5, which compared favourably with reports
of the NNTs for other interventions. I too interpret this
as evidence for worthwhile e⁄cacyof this treatment. In-
terestingly, a similar analysis of our own data on health
status changes after treatment of patients with chronic
obstructive pulmonary diseasewith salmeterol (14), pro-
duced anNNTof 5.0.When I discussed this with a collea-
gue, he expressed some dismay. In his view a good NNT
was 2, i.e. treat two patients and expect at least one to
improve.
KNOWLEDGEVSBEHAVIOUR
Education increases knowledge, but may not produce
improved behaviour. For example, in a South American
study of prescribing for childhood diarrhoea, over 70%
of doctors prescribed antibiotics inappropriately despite
good knowledge of the appropriate treatment (oral re-
placement therapy) (15). In another South American
study of the same condition, an examination of doctors
case records suggested that they prescribed less oral re-
placement therapy and more antibiotic and anti-diar-
rhoeal agents than they said they did when interviewed
(16). The principle reason for this appeared to be that
doctors lacked the ability or motivation to deal with dif-
¢cultmothers.The authors of one of these South Amer-
ican studies concluded: ‘‘prescribing practices seemed to
be more related to agreement with social expectations
and the caretakers’ perception of the physicians’ role
than they were to standard biomedical rules’’ (15). De-
spite the di¡erence in socio-economic conditions, this
conclusion was very similar to the views about evi-
dence-based medicine expressed by British GPs dis-
cussed earlier (2).
GETTINGEVIDENCE INTOPRACTICE
Therehavebeenverymany studies ofmethods to change
patterns of clinical behaviour. A recent overview sum-
marized the ¢ndings from 44 di¡erent systematic re-
views of this topic (17). Ine¡ective interventions include
published guidelines, local guidelines (unless accompa-
nied by educational interventions) and mail shots. More
e¡ective interventions appear to be: feedback (patient
report being the most important), continuing medical
education, educational outreach (e.g. prescribing advi-
sor), patient-mediated interventions, and computer-
based decision support.
One speci¢c e¡ective intervention, educational out-
reach in the form of a prescribing advisor, is worth spe-
ci¢cmention.Results from a randomized controlled trial
have shown that therapeutic decision making was im-
provedwhen a pharmacist outreach programmewas im-
plemented (18). This process, also known as academic
detailing is largely an American development (19), but is
570 RESPIRATORYMEDICINEnow being formally tested in the U.K. and other coun-
tries. In the U.K., many primary care groups employ
pharmacy advisors inpart to carryout this type of work.
A recent report described the results of a partnership
between GPs, nurses and community pharmacists (20).
This group identi¢ed three goals, one of which was a
switch from branded beclomethasone to generic beclo-
methasone on cost grounds. The GPs were visited four
times a year by a specially trained pharmacist. During
this time, therewas a signi¢cant increase in theprescrib-
ing of generic beclomethasone. Whilst this prescribing
initiativewas costdriven, a similar approach isbeingused
to implement the British Thoracic Society Asthma
Guidelines in general practice (21).
It is clear that there are no simple solutions and that
some solutions may be situation- or culturally speci¢c.
Multi-faceted interventions involving a number of di¡er-
ent agents for change are likely to be more successful
than simple interventions. This conclusion is supported
by the results of qualitative surveys of physician attitudes





It is clear from the foregoing discussion that getting evi-
dence-based practice into routine asthma management
is a slow and complex process. However, there is now
good evidence from randomized controlled trials that
physician education can improve paediatric asthmaman-
agement (22). This programme was comprehensive and
centred upon providing guidance to physicians to enable
them to develop a partnership with their patients. The
approach was based upon evidence that the patient
should be the primary manager of their chronic disease
and that the role of the physician andnursewas to coach
thepatient and devise thebest therapeutic regimen (23).
Asthma patient treated by such ‘‘educated’’ physicians
weremore likely to receive prophylactic therapy, to have
been taught how to use a metered dose inhaler and to
have fewer emergency visits to the GP.There was no ef-
fect on emergency department visits or hospital admis-
sions. Perhaps more importantly, among the children
who received inhaled corticosteroid therapy, those who
were treated by physicians who had participated in the
intervention programme also had fewer emergency de-
partment visits and hospital admissions.
CONCLUSIONS
A clear message comes from the material reviewed in
this paper. There is an abundance of good quality evi-
dence coming from clinical trials, systematic reviewsandemergingevidence-basedguidelines to guide decision
making in asthma management. To be implemented ef-
fectively, this evidence has to be presented in a compre-
hensible way. Programmes to ensure its incorporation
into a clinician’s practice will have to be comprehensive
and sensitive to all the other pressures clinicians experi-
ence during their daily work. Finally, the role of the pa-
tient in managing their asthma is crucial.Clinicians need
training in conveying the best possible evidence to their
patients, only thenwill it be truly implemented.
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